Losartan Potassium Tablet, Film Coated
Product Images NDC 68788-8189

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-8189). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium Tab Usp 50mg (68ed9727 987e 4bb6 98b4 B98150bb6404 00)

Losartan Potassium Tab is a medication prescribed only to the patient mentioned on the package. Any transfer of the drug to another person is prohibited by federal law. The medication is commonly used as a generic substitute for Cozaarg E E- Losartan Potassium Tab. Each tablet contains 50mg of Losartan potassium. The tablets are white, scored, and imprinted with S 113. The package contains 508g of Losartan Potassium Tab USP. The manufacturer of the drug is Soleo HealthCare U.S., LLC. The package has an expiration date and lot number for identification purposes. There is also a warning provided in the package.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

FDA Label Image

Figure 1 (Spl Image2 Figure1)

The text provides information on a comparison of two medications, Atenolol and Losartan Potassium, for the primary endpoint in a study. There is data indicating an adjusted risk reduction of 13% with a p-value of 0.021. The study was conducted over a period of 66 months, with data being collected at various intervals.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

This text appears to be a comparison study between Atenolol and Losartan Potassium, two drugs often used in the treatment of high blood pressure. The study includes a risk reduction percentage of 25% with a p-value of 0.001. The remaining text displays a graph or table indicating the percentage of patients experiencing fatal/non-fatal stroke over a period of 66 months.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

FDA Label Image

Figure 4 (Spl Image5 Figure4)

This is a chart showing the percentage of patients experiencing an event (unspecified) over a period of 48 months. The chart compares the group that received Losartan Potassium with the group that received a placebo. The Losartan Potassium group had a risk reduction of 16.1% compared to the placebo group, with a p-value of 0.022.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.